Esophageal cancer: emerging therapeutics

Rogers, Jane E.; Sewastjanow-Silva, Matheus; Waters, Rebecca; Ajani, Jaffer A.

doi:10.1080/14728222.2022.2036718

Cited by 89 publications

(58 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the gradual advancement of current molecular research on EC, increasing attention has been paid to EC immunotherapy [ 29 ]. PD-1 is present in memory CD8 + T cells, memory CD4 + T cells, mucosal-associated invariant T (MAIT) T-cells, gamma delta (Gd) T-cells, regulatory T-cells (Tregs), monocytes, and natural killer (NK) cells, which is a transmembrane protein [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis

Wang

Yang

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of adverse events. Suitable randomized controlled trials (RCTs) were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Moreover, we searched for conference abstracts from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) to compare the comprehensive curative effects of PD-1 inhibitors or single-agent therapy in terminal or metastatic EC. The primary outcome indicators were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Treatment-related adverse events (TRAEs) were the secondary outcome indicators. We compared the previously mentioned indicators of the two treatment modalities using Stata software (version 12.0). We compared the long-term survival rates of both treatment groups and analyzed the possible factors affecting OS. We selected five RCTs with 2197 patients as study subjects. Compared with conventional single-agent chemotherapy, PD-1 inhibitors greatly improved the patients’ OS (HR = 0.77, 95% CI 0.70–0.85, P < 0.001 ), but PFS (HR = 0.93, 95% CI 0.77–1.12, P = 0.431 ) and DCR (RR = 0.93, 95% CI 0.71–1.22, P = 0.609 ) were not greatly improved. Moreover, PD-1 inhibitors improved ORR (RR = 1.83, 95% CI 1.16–2.89, P = 0.009 ) and decreased TRAEs (RR = 0.76, 95% CI 0.61–0.95, P < 0.001 ) and serious TRAEs (RR = 0.40, 95% CI 0.32–0.49, P < 0.001 ). Further analysis demonstrated that OS was affected by age, sex, region, smoking history, and the number of organ and lymph node metastases. Compared with the traditional single chemotherapy drugs, PD-1 inhibitors can achieve higher OS and ORR, fewer and more serious TRAEs, and better efficacy and safety for second-line therapy of terminal or metastatic EC.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis

Wang

Yang

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“… 5 Most esophageal cancers are SCC or AC. 6 , 7 In patients with esophageal cancer, SCC accounts for the overwhelming majority of cases worldwide.…”

Section: Pathology Of Esophageal Cancermentioning

confidence: 99%

Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040

et al. 2022

View full text Add to dashboard Cite

Esophageal cancer is a familiar malignancy with high incidence and mortality, and the overall prognosis is poor. The numbers of cases of and deaths from esophageal cancer have risen rapidly in recent decades. It is one of the most malignant cancers, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. Here, we present the global epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040 at different geographical levels of continents, regions and countries, and analyze them by gender, race, geographic region and human development index. We summarize the prospects for the esophageal cancer burden and risk factors in different areas, which will be useful for global esophageal cancer clinical therapy and cancer control planning.

show abstract

“…According to statistics, the global incidence of EC in 2020 was about 604,000 cases, accompanied by 544,000 deaths [ 2 ]. At present, the effective means for treatment of EC mainly includes surgery, preoperative radiotherapy and chemotherapy or perioperative chemotherapy, immunotherapy and so on [ 3 ]. In recent years, great progress has been made in the immunotherapy of EC, but it is still not ideal for patients with advanced metastasis of EC.…”

Section: Introductionmentioning

confidence: 99%

The role of ferroptosis in esophageal cancer

Wang

Zhu

et al. 2022

Cancer Cell Int

View full text Add to dashboard Cite

Esophageal cancer is one of the most common cancers with high mortality rate around the world. Although the treatment strategy of this disease has made great progress, the prognosis of advanced patients is not ideal. Ferroptosis, a novel regulatory cell death model, that is different from traditional apoptosis and characterized by increased Fenton reaction mediated by intracellular free iron and lipid peroxidation of cell membrane. Ferroptosis has been proved to be closely linked to a variety of diseases, especially cancer. This review aims to summarize the core mechanism of ferroptosis in esophageal cancer, the regulation of ferroptosis signaling pathway and its current application. At the same time, we emphasize the potential and prospect of ferroptosis in the treatment of esophageal cancer. Collectively, targeting ferroptosis pathway may provide new insights into the diagnosis, treatment and prognosis of esophageal cancer.

show abstract

Esophageal cancer: emerging therapeutics

Cited by 89 publications

References 63 publications

Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis

Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis

Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040

The role of ferroptosis in esophageal cancer

Contact Info

Product

Resources

About